modelNadroparin
Extends from Pharmacolibrary.Drugs.ATC.B.B01AB06.
Information
| name: | Nadroparin | |
| ATC code: | B01AB06 | route: | subcutaneous |
| compartments: | 1 | |
| dosage: | 2850 | mg |
| volume of distribution: | 4.0 | L |
| clearance: | 1.0 | L/h |
| other parameters in model implementation | ||
Nadroparin is a low molecular weight heparin (LMWH) used for the prevention and treatment of thromboembolic diseases, such as deep vein thrombosis and pulmonary embolism. It acts as an anticoagulant by potentiating the inhibition of factor Xa and to a lesser extent thrombin. Nadroparin is widely used and approved in many countries for clinical use.
Pharmacokinetics
Pharmacokinetics reported in healthy adult volunteers after subcutaneous administration.
References
Romano, LGR, et al., & Preijers, T (2023). Population pharmacokinetics of nadroparin for thromboprophylaxis in COVID-19 intensive care unit patients. British journal of clinical pharmacology 89(5) 1617–1628. DOI:10.1111/bcp.15634 PUBMED:https://pubmed.ncbi.nlm.nih.gov/36495312
Piwowarczyk, P, et al., & Czuczwar, M (2023). Population Pharmacokinetics and Probability of Target Attainment Analysis of Nadroparin in Different Stages of COVID-19. Clinical pharmacokinetics 62(6) 835–847. DOI:10.1007/s40262-023-01244-4 PUBMED:https://pubmed.ncbi.nlm.nih.gov/37097604
Piwowarczyk, P, et al., & Borys, M (2025). Is an extended dose of subcutaneous nadroparin anticoagulation equally safe and feasible compared to unfractionated heparin anticoagulation during extracorporeal membrane oxygenation in critically ill COVID-19 patients?. Anaesthesiology intensive therapy 57(1) 59–65. DOI:10.5114/ait/202605 PUBMED:https://pubmed.ncbi.nlm.nih.gov/40237531
Parameters
| Type | Name | Default | Description |
|---|---|---|---|
| Modelica.Units.SI.Mass | weight (from PK_1C) | 75 | patient weight (kg) |
| Modelica.Units.SI.SpecificVolume | VdPerKg (from PK_1C) | 0.9 | Volume of distribution (L/kg) |
| Modelica.Units.SI.MassFraction | F (from PK_1C) | 0.8 | bioavailiability (0-1) |
| Pharmacolibrary.Types.Clearance | Cl (from PK_1C) | 20 | clearance |
| Modelica.Units.SI.Time | adminTime (from PK_1C) | 60 | first administration time (s) |
| Modelica.Units.SI.Time | adminDuration (from PK_1C) | 600 | administration duration (s) |
| Modelica.Units.SI.Time | adminPeriod (from PK_1C) | 8*60*60 | period of administration (default 8 hours)(s) |
| Pharmacolibrary.Types.Mass | adminMass (from PK_1C) | 1000 | administration mass (mg) |
| Integer | adminCount (from PK_1C) | 8 | number of dose administered (1) |
| Pharmacolibrary.Types.Volume | Vd (from PK_1C) | VdPerKg*weight | Volume of distribution (m3) |
| Pharmacolibrary.Types.MassConcentration | Cmin (from PK_1C) | 0.004 | minimal therapeutic range |
| Pharmacolibrary.Types.MassConcentration | Cmax (from PK_1C) | 0.008 | minimal therapeutic range |
| Pharmacolibrary.Types.MassConcentration | Ctox_peak (from PK_1C) | 0.012 | toxicity peak level |
| Pharmacolibrary.Types.MassConcentration | Ctox_trough (from PK_1C) | 0.006 | toxicity trough level |
Connectors
| Type | Name | Default | Description |
|---|---|---|---|
| Types.ConcentrationOutput | C_central (from PK_1C) | ||
| Interfaces.ConcentrationPort_b | centralCPort (from PK_1C) |
Components
| Type | Name | Default | Description |
|---|---|---|---|
| Pharmacokinetic.NoPerfusedTissueCompartment | central (from PK_1C) | ||
| Pharmacokinetic.ClearanceDrivenElimination | elim (from PK_1C) | ||
| Sources.PeriodicDose | periodicDose (from PK_1C) | ||
| Modelica.Units.SI.Time | t1_2 (from PK_1C) | elimination half-life |
Revisions
- 06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)